Advaxis, Inc., a clinical-stage biotechnology company, focuses on the discovery, development, and commercialization of proprietary Listeria monocytogenes (Lm) technology antigen delivery products in the United States. The company is developing ADXS-PSA, which is in Phase 2 clinical trials for the treatment of metastatic prostate cancer; ADXS-503 that is in Phase 1/2 clinical trials for the treatment of non-small cell lung cancer; and ADXS-504 for the treatment of prostate cancer. It is also conducting clinical studies of Lm Technology immunotherapies in the following areas of disease focused hotspot/off-the-shelf neoantigen-directed therapies; human papilloma virus-associated cancers; and prostate cancer. The company has collaborations and partnerships with Merck & Co., Inc.; OS Therapies, LLC; Aratana Therapeutics Inc.; Biocon Limited; Global BioPharma Inc.; Knight Therapeutics Inc; and others. Advaxis, Inc. was founded in 2002 and is based in Princeton, New Jersey.
Search:
You do not have permission to access this chart.
Please Sign Up or Login
News for Advaxis, Inc. (ADXS)
minutes ago | Banggood.com
58 minutes ago | Aliexpress.com
4 days ago | GlobeNewsWire
0 months ago | PRNewsWire
a month ago | Benzinga
a month ago | GlobeNewsWire
a month ago | GlobeNewsWire
a month ago | Business Wire
a month ago | PRNewsWire
a month ago | Pulse2
a month ago | GlobeNewsWire
Advaxis Reports Second Quarter Ended April 30, 2021 Financial Results and Provides a Business Update
2 months ago | GlobeNewsWire